Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVX-108 with Radiation and Temozolomide in Glioblastoma
NCT02189109Phase 1Completed
- Sponsor
- NuvOx Therapeutics
- Start
- May 2014
- Primary completion
- Aug 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflenapent in glioblastoma multiforme (GBM), sponsored by NuvOx Therapeutics. Primary endpoint: Safety and Tolerability of NVX-108 in Combination with Radiation and Temozolomide at 6 months. Started May 2014; status: completed.
02
Drugs
perflenapent
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02189109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189109.